Quotables
"What can be more palpably absurd than the prospect held out of locomotives traveling twice as fast as stagecoaches?"
The Quarterly Review ; March edition, 1825
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7560479 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists This invention relates to derivatives of 3,6-disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal syst... | 07/14/2009 |
| 7517905 | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists This invention relates to the derivatives of substituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal system... | 04/14/2009 |
| 7488748 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointes... | 02/10/2009 |
| 7482463 | Amorphous form of esomeprazole salts The invention relates to an amorphous form of the salts of the (-) enantiomer or (S)-enantiomer of omeprazole, i.e., esomeprazole. The invention also relates to processes for preparing amorphous esomeprazole salts and pharmaceutical compositions that include the amo... | 01/27/2009 |
| 7465751 | 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the re... | 12/16/2008 |
| 7462712 | Process for the preparation of imipenem The present invention relates to an improved process for the preparation of imipenem comprising reacting a bicyclo ketone precursor of the Formula II, wherein R is a protecting group, with a phosphorohalidate in the presenc... | 12/09/2008 |
| 7410993 | 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0] hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary an... | 08/12/2008 |
| 7399779 | 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists This invention generally relates to the derivatives of novel 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia for the treatment of various diseases of the respiratory, urinar... | 07/15/2008 |
| 7332600 | Process for the preparation of crystalline imipenem The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity, which comprises dissolving crude imipenerm in warm water to which some base has been added to obtain a solution, subjecting the re... | 02/19/2008 |
| 7265147 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0]hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary and... | 09/04/2007 |
| 7241885 | Process for the isolation of crystalline imipenem The present invention relates to a cost effective and industrially advantageous process for the preparation of imipenem of high purity comprising the steps of treating an aqueous solution containing imipenem with an organic solvent, wherein the imipenem is not lyoph... | 07/10/2007 |
| 7232835 | 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists This invention relates to derivatives of 3,6-disubstituted azabicyclo compounds. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal s... | 06/19/2007 |
| 7148355 | Process for the preparation of repaglinide The present invention relates to a cost effective and industrially advantageous process for the preparation of repaglinide. ... | 12/12/2006 |
| 7129365 | Process for the preparation of acitretin The present invention relates to a cost effective and industrially useful process for the preparation of substantially pure acitretin. More specifically, the present invention relates to the preparation of acitretin of high purity and yield. ... | 10/31/2006 |
| 7115281 | Processes for the preparation of oral dosage formulations of modafinil The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms ... | 10/03/2006 |
| 7084301 | Tamsulosin derivative The optically active compound, R (−)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide in good optical purity, a metabolite of the α1-adrenergic blocking agent tamsulosin, and methods for the preparation thereof. Pharmaceutical ... | 08/01/2006 |
| 7078430 | HMG CoA-reductase inhibitors The invention relates to particular hydroxyl and protected hydroxyl derivatives of compounds known to be useful as HMG CoA-reductase inhibitors. In particular, herein are provided hydroxyl and protected hydroxyl compounds of Formula I ... | 07/18/2006 |
| 7078534 | Process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (imipenem monohydrate) The present invention relates to a cost effective and commercially viable process for the preparation of crystalline N-formimidoyl thienamycin monohydrate (Imipenem monohydrate) of Formula I. ... | 07/18/2006 |
| 7052886 | Process for the isolation of lovastatin The process for the preparation and isolation of the hypolipaemic active substance lovastatin in substantially pure form having a purity of at least 95% which comprises lactonizing the mevinolinic acid to lovastatin in a totally aqueous medium. ... | 05/30/2006 |
| 7045618 | Cefpodixime proxetil The present invention relates to an improved and cost effective process for the industrial manufacture of cefpodoxime proxetil. More specifically, the present invention relates to the preparation of cefpodoxime proxetil of high purity and yield. The process comprise... | 05/16/2006 |
| 7005516 | Derivatives of monosaccharides as cell adhesion inhibitors This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-α-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell a... | 02/28/2006 |
| 7005422 | Derivatives of monosaccharides as cell adhesion inhibitors This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-α-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell a... | 02/28/2006 |
| 6960356 | Orally administered drug delivery system providing temporal and spatial control A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swe... | 11/01/2005 |
| 6921839 | Synthesis of N,N-dimethyl-3-(4-methyl) benzoyl propionamide a key intermediate of zolpidem The present invention relates to an improved and industrially advantageous process for the preparation of N,N-dimethyl-3-(4-methyl)benzoyl propionamide of Formula I, which is a key intermediate in the synthesis of zolp... | 07/26/2005 |
| 6919450 | Process for the preparation of benazepril The present invention relates to an improved process for the preparation of trifluoromethanesulfonic ester of ethyl (R)-2-hydroxy-4-phenylbutyrate, referred to here as triflate in structural Formula I, and to the use of this compound as intermediate for the preparat... | 07/19/2005 |
| 6914064 | 1,4-Disubstituted piperazine derivatives useful as uro-selective α1-adrenoceptor blockers The present invention relates to a novel 1,4-disubstituted piperazine derivatives of Formula I, and their pharmaceutically acceptable acid addition salts having excellent uro-selective α1-adrenoceptor antag... | 07/05/2005 |
| 6894188 | Tamsulosin derivative The optically active compound, R(−)-5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-hydroxybenzenesulfonamide in good optical purity, a metabolite of the α1-adrenergic blocking agent tamsulosin, and methods for the preparation thereof. Pharmaceutical c... | 05/17/2005 |
| 6890957 | Liquid formulation of metformin The present invention is directed to a liquid formulation of metformin or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of metformin or its pharmaceutically acceptable salt, in a liq... | 05/10/2005 |
| 6833452 | Process for the preparation of highly pure crystalline (R,S)—cefuroxime axetil A process for the preparation of highly pure crystalline form of cefuroxime-1-acetoxyethyl ester (cefuroxime axetil) from cefuroxime by reacting an amine salt of cefuroxime with an esterifying reagent. ... | 12/21/2004 |
| 6822119 | Process for the preparation of tolterodine The present invention relates to a cost effective and industrially advantageous process for the preparation of tolterodine and pharmaceutically acceptable salts thereof. ... | 11/23/2004 |
| 6812344 | 1-(4-Arylpiperazin-1-yl)-ω-[N-(α,ω-dicarboximidoL)]-alkanes useful as uro-selective α1-adrenoceptor blockers The present invention relates to certain novel piperazine derivatives having protracted uro-selective α1-adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treatin... | 11/02/2004 |
| 6803468 | Process for the synthesis of n-(5-methylnicontinoyl)-4 hydroxypiperidine, a key intermediate of rupatadine The present invention relates to an improved and industrially advantageous process for the preparation of N-(5-methylnicotinoyl)-4-hydroxypiperidine of Formula I, as shown in the accompanied drawings. This compound is a key intermediate for the synthesis of rupatadi... | 10/12/2004 |
| 6740337 | Bioavailable dosage form of isotretinoin The present invention relates to a bioavailable pharmaceutical composition of 13-cis vitamin A acid (also known as 13-cis retinoic acid and isotretinoin) and a process for preparing the same. 13-cis vitamin A acid is a relatively water insoluble compound that degrad... | 05/25/2004 |
| 6734307 | Oxazolidinone derivatives as antimicrobials The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds a... | 05/11/2004 |
| 6710049 | Azole compounds as anti-fungal agents The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared with presently available agents in this class and the processes for the preparation thereof. This invention also relates to ... | 03/23/2004 |
| 6602999 | Amorphous form of cefpodoxime proxetil A novel process for the production of an improved amorphous form of cefpodoxime proxetil [(6R-[6,7ଲ(Z))]-7-{E(2-Amino-4-thiazolyl)(methoxyimino)acetyl] amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2. 0]oct-2-ene-2-carboxylic acid-... | 08/05/2003 |
| 6565877 | Taste masked compositions A taste masked composition which comprises a bitter tasting drug, a combination of two enteric polymers comprising, a methacrylic acid copolymer and a phthalate polymer is described. The composition of the present invention is prepared by dissolving the a... | 05/20/2003 |
| 6559187 | Liquid formulation of metformin The present invention is directed to a liquid formulation of metformin or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of metformin or its pharmaceutically acceptable sal... | 05/06/2003 |
| 6534494 | Process for the preparation of cefuroxime axetil in an amorphous form A process for preparing cefuroxime axetil in substantially amorphous form comprises forming a mixture of crystalline cefuroxime axetil and at least one pharmaceutically acceptable excipient, and subjecting the mixture to milling for a period of time suffi... | 03/18/2003 |
| 6441226 | Process for the preparation of isotretinoin The present invention relates to a process for the preparation of 13-cis isomer of Vitamin A acid, commonly known as isotretinoin, in a single step.... | 08/27/2002 |
